Alexandre M, Prague M, Lhomme E, Lelievre JD, Wittkop L, Richert L et al. (2024). Definition of viroIogical endpoints improving the design of HIV cure strategies using analytical antiretroviral treatment interruptionmedRxiv.

Falqui M, Perdiguero B, Coloma R, Albert M, Marcos-Villar L, McGrail JP. (2023). An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses. Front Cell Infect Microbiol ;13:1187193. doi: 10.3389/fcimb.2023.1187193. PMID: 37313341; PMCID: PMC10258332

Lucas J, Lin LY, Paul N, Laumond G, Klingler J, Schmidt S. (2023). Identification of early-induced broadly neutralizing activities against transmitted founder HIV strains. AIDS. 2023 Jan 1;37(1):43-49. doi: 10.1097/QAD.0000000000003371. Epub 2022 Sep 16. PMID: 36001527; PMCID: PMC9794156.

Pedenko B, Sulbaran G, Guilligay D, Effantin G, Weissenhorn W. (2023). SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses. 2023; 15(2):558.

Westphal T, Mader M, Karsten H, Cords L, Knapp M, Schulte S, et al. (2023). Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronavirusesFront Immunol.

Jensen BEO, Knops E, Cords L, Lübke N, Salgado M, Busman-Sahayet K, et al. (2023). In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantationNat Med.

Horvath A, Rogers L, Pollakis G, Baranov O, Pieroth N, Joseph S, et al. (2023). Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? Fronteirs in Immunology.

Maliqi L, Friedrich N, Glögl M, Schmutz S, Schmidt D, Rusert P et al. (2023). Assessing immunogenicity barriers of the HIV-1 envelope trimernpj vaccines.

Prins HAB, Crespo R, Lungu C, Rao S, Li L, Overmars RJ, et al. (2023). The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapySciences Advances.

Perdiguero B., Hauser A., Gómez CE., Peterhoff D., Sideris E., Sorzano COS., et al. (2023). Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env proteinFronteirs in Immunology.

Riepler L., Frommelt LS., Wilmschen-Tober S., Mbuya W., Held K., Volland A., von Laer D., Geldmacher C., Kimpel J. (2023). Therapeutic Efficacy of a VSV-GP-based Human Papilloma Virus Vaccine in a Murine Cancer Model. 10.1016/j.jmb.2023.168096. Epub 2023 Apr 20

Glögl M., Friedrich N., Cerutti G. et al. (2023). Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization. Nat Struct Mol Biol.

Polo-Megías D, Cano-Muñoz M, Berruezo AG, Laumond G, Moog C, Conejero-Lara F. (2022). Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins. Int J Mol Sci. 2022 Dec 7;23(24):15511. doi: 10.3390/ijms232415511. PMID: 36555153; PMCID: PMC9778920.

Cano-Muñoz M, Polo-Megías D, Cámara-Artigas A, Gavira JA, López-Rodríguez MJ, Laumond G. (2022). Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity. Int J Biol Macromol. 2022 Dec 1;222(Pt B):2467-2478. Epub 2022 Oct 8.

Karsten H, Cords L, Westphal T, Knapp M, Brehm TT, Hermanussenet L., et al. (2022). High‐resolution analysis of individual spike peptide‐specific CD4 + T‐cell responses in vaccine recipients and COVID‐19 patientsClin Transl Immunolog.

Kolbe K, Wittner M, Hartjen P, Hüfner AD, Degen O, Ackermann C., et al. (2022). Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease ProgressionFront Immunology.

Sulbaran G, Maisonnasse P, Amen A, Effantin G, Guilligay D, Dereuddre-Bosquet N, et al. (2022). Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Rep Med. 2022 Jan 24;3(2):100528. PMID: 35233549; PMCID: PMC8784613.

Feraoun Y, Palgen JL, Joly C, Tchitchek N, Marcos-Lopez E, Dereuddre-Bosquet N, et al. (2022). The route of Vaccine Administration determines whether blood neutrophils undergo long-term phenotypic modifications. Frontiers in Immunology. 2022;12.

Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Front Immunol. 2021 Apr 20;12:645210. PMID: 33959127; PMCID: PMC8093451.

Malatinkova E, Thomas J, De Spiegelaere W, Rutsaert S, Geretti AM, Pollakis G, et al. (2021). Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences. Life. 2021; 11(12):1410.

Hauser A, Carnell G, Held K, Sulbaran G, Tischbierek N, Rogers L, et al. (2021). Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines. 2021; 9(7):750.

Friedrich N, Stiegeler E, Glögl M, Lemmin T, Hansen S, Kadelka C, et al. (2021). Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. Nat Commun 12, 6705.

Lungu C, Banga R, Gruters R, & Procopio AF. (2021). Inducible HIV-1 Reservoir Quantification: Clinical Relevance, Applications and Advancements of TILDA. Front. Microbiol. 2021 Jun 15.

Peterhoff D, Thalhauser S, Sobczak JM, Mohsen MO, Voigt C, Seifert N, et al. (2021). Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines, 9(6):642. 2021 Jun 11.

Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra, RJ, et al. (2021). Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nature communications12(1), 2475. 2021 Apr 30.

Msafiri F, Joachim A, Held K, Nadai Y, Chissumba RM, Geldmacher C, et al. (2020). Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers. Microganisms. 2020 Nov 4;8(11):1722. PMID: 33158007; PMCID: PMC7693996.

Hähnel V, Peterhoff D, Bäuerlein V, Brosig A-M, Pamler I, Johnson C, et al. (2020). Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality. PLoS ONE 15(12): e0243967.

Eberhard JM, Angin M, Passaes C, Salgado M, Monceaux V, Knops E et al. (2020). Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Sci Transl Med ;12(542):eaay9355. doi: 10.1126/scitranslmed.aay9355. PMID: 32376772.

Highton AJ, Diercks B-P, Möckl F, Martrus G, Sauter J, Schmidt AH, et al. (2020). High metabolic function and resilience of NKG2A-educated NK Cells. Frontiers in Immunology. 2020;11.

Thomas J, Ruggiero A, Paxton WA, Pollakis G. (2020). Measuring the success of HIV-1 cure strategiesFront Cell Infect Micro. 

Lungu C, Procopio FA, Overmars RJ, Beerkens R, Voermans J, Rao S, et al. (2020). Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses, 12(9), 973. 2020 Sep

Joachim A, Ahmed M, Pollakis G, Rogers L, Hoffmann VS, Munseri P, et al. (2020). Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost. Frontiers in immunology11, 719. 2020 Apr 28.

Palgen JL, Tchitchek N, Rodriguez-Pozo A, Jouhault Q, Abdelhouahab, Dereuddre-Bosquet N, et al. (2020). Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. npj Vaccines 5, 24.

Thomas J, Ruggiero A, Procopio FA, Pantaleo G, Paxton WA, Pollakis G. (2019). Comparative analysis and generation of a robust HIV-1 DNA quantification assayJ Virol Methods. 

Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, et al. (2019). Update on FC-mediated antibody functions against HIV-1 beyond neutralization. Frontiers in Immunology. 2019;10.

Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, et al. (2019). Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines. 2019; 7(4):178.

Wilmschen S, Schmitz JE, Kimpel J. (2019). Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Vaccines. 2019; 7(3):119.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, et al. (2019). Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. Viruses. 2019; 11(2):159.

Perdiguero B, Gómez CE, García-Arriaza J, Sánchez-Corzo C, Sorzano CÓS, Wilmschen S, et al. (2019). Heterologous combination of VSV-gp and NYVAC vectors expressing HIV-1 trimeric GP145 env as vaccination strategy to induce balanced B and T cell immune responses. Frontiers in Immunology. 2019;10.

Pérez P, Marín MQ, Lázaro-Frías A, Sorzano CÓS, Di Pilato M, Gómez CE, Esteban M, García-Arriaza J. (2019). An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design. Vaccines. 2019; 7(4):208.

Perdiguero B, Sánchez-Corzo C, Sorzano COS, Saiz L, Mediavilla P, Esteban M, Gómez CE. (2019). A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses. Viruses. 2019; 11(2):160.

Raman SC, Mejias-Pérez E, Gomez CE, García-Arriaza J, Perdiguero B, Vijayan A, et al. (2019). The envelope-based fusion antigen gp120c14k forming hexamer-like structures triggers T cell and neutralizing antibody responses against HIV-1. Frontiers in Immunology, 10.

Wittner M, Schlicker V, Libera J, Bockmann JH, Horvatits T, Seiz O, et al. (2019) Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. PLOS ONE 14(7): e0220008.

Moore C, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, et al. (2019). Multi-arm multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV, 6(5):e334-e340. 2019 May 01.

Nadai Y, Held K, Joseph S, Ahmed M, Hoffmann VS, Peterhoff D, et al. (2019). Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. Frontiers in immunology10, 717. 2019 Apr 24.

Jean-Louis P, Tchitchek N, Huot N, Elhmouzi-Younes J, Lefebvre C, Rosenbaum P, et al. (2019). NK cell immune responses differ after prime and boost vaccination. Journal of Leukocyte Biology, Volume 105, Issue 5, May 2019, Pages 1055–1073.

Commenges D., Alkhassim C., Gottardo R., Hejblum B., Thiébaut R. (2018). Cytometree: A binary tree algorithm for automatic gating in cytometry analysis. Wiley.

Wilmschen S, Banki Z, von Laer D, Kimpel J. (2018). Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral VectorJ Vis Exp.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, et al. (2018). Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE 13(12): e0208345.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, et al. (2018). Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Human Gene Therapy.Sep 2018.1011-1028.

Pfeifer C, Highton AJ, Peine S, Sauter J, Schmidt AH, Bunders MJ, et al. (2018). Natural killer cell education is associated with a distinct glycolytic profile. Frontiers in Immunology. 2018;9.

Wagner R, Asbach B. (2018). Dürfen wir noch auf eine HIV-Impfung hoffen? MMW - Fortschritte der Medizin 160 (Suppl 2), 24–27.

Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, et al. (2018). Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Sci Rep 8, 3087.

Parsons MS, Le Grand R, Kent SJ. (2018). Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses. 2018; 10(6):333.

Kratochvil S, McKay PF, Chung AW, Kent SJ, Gilmour J, Shattock RJ. (2017).  Immunoglobulin G1 allotype influences antibody subclass distribution in response to HIV GP140 vaccination. Frontiers in Immunology. 2017;8.

Leal L, Lucero C, Gatell JM, Gallart T, Plana M, García F. (2017). New challenges in therapeutic vaccines against HIV infection. Expert Review of Vaccines, 16:6, 587-600.

Mayr LM, Su B, Moog C. (2017). Non-neutralizing antibodies directed against HIV and their functions. Frontiers in Immunology. 2017;8.

Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, et al. (2017). A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in immunology8, 595. 2017 May 24.

Peterhoff D, Wagner R. (2017). Guiding the long way to broad HIV neutralization. Current Opinion in HIV and AIDS, 12(3):p 257-264, May 2017.

Wagner R. (2017). Effective HIV vaccine: narrow path to broadly neutralizing antibodies? Current Opinion in HIV and AIDS, 12(3):p 191-194, May 2017.

Asbach B, Wagner R. (2017). Particle-based delivery of the HIV envelope protein. Current Opinion in HIV and AIDS, 12(3):p 265-271, May 2017.

Medina-Ramírez M, Sanders RW, Sattentau QJ. (2017). Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current Opinion in HIV and AIDS, 12(3):p 241-249, May 2017.

Related publications from EHVA partners
Vollmers S, Lobermeyer A, Niehrs A, Fittje P, Indenbirken D, Nakel J, et al. (2022). Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-C. Front Immunol. doi:10.3389/fimmu.2022.922252. PMID: 35911762; PMCID: PMC9334850.

Höfle J, Trenkner T, Kleist N, Schwane V, Vollmers S, Barcelona B, Niehrs A, et al. (2022). Engagement of TRAIL triggers degranulation and IFNγ production in human natural killer cells. EMBO Rep. 2022 Aug 3;23(8):e54133. PMID: 35758160; PMCID: PMC9346491.

Schwane V, Huynh-Tran VH, Vollmers S, Yakup VM, Sauter J, Schmidt AH, et al. (2020). Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells. Front Immunol. MID: 33335526; PMCID: PMC7736243.

van Stigt Thans T, Akko JI, Niehrs A, Garcia-Beltran WF, Richert L, Stürzel CM, et al. Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression. J Virol. 2019 Sep 30;93(20):e00719-19. PMID: 31375574; PMCID: PMC6798123

Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, et al. (2017). Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 2017 Aug 29;20(9):2251-2261. PMID: 28854372; PMCID: PMC5583508.


  • EHVA P01: a phase I, prophylactic HIV vaccine trial

    EHVA P01 / ANRS VRI08 is a phase I, prophylactic HIV vaccine trial to evaluate the safety and...

    Read More …

  • EHVA Latest News

    EHVA latest newsletter is available...

    Read More …

  • EHVA Halts Phase II EHVA-T02 Clinical Trial of a Candidate Therapeutic HIV Vaccine and Immunotherapy Drug

    The European HIV Vaccine Alliance (EHVA) has announced that the EHVA T02 / ANRS VRI07 trial, a...

    Read More …


This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032